Horan Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Horan Securities’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-62	Closed	-$7K	–	412
2020 Q2	$7K	Hold	62	–	–	0.01%	223
2020 Q1	$6K	Buy	+62	New	+$6.08K	0.01%	163

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Horan Securities's ALXN Position: Q3 2020 in Review

Horan Securities sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 62 shares — an estimated $7K sold.

Horan Securities first reported a position in ALXN in Q1 2020 and held it in 2 quarters. The position peaked at $7K in Q2 2020. 707 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

Horan Securities reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Horan Securities sold 62 Alexion Pharmaceuticals shares in Q3 2020, an estimated $7K.
Horan Securities first reported a position in Alexion Pharmaceuticals in Q1 2020 and held it in 2 quarters.
Horan Securities's Alexion Pharmaceuticals position peaked at $7K in Q2 2020.
707 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Horan Securities's 13F filing for Q3 2020, filed 4 Nov 2020.